JP2023537410A5 - - Google Patents
Info
- Publication number
- JP2023537410A5 JP2023537410A5 JP2023509739A JP2023509739A JP2023537410A5 JP 2023537410 A5 JP2023537410 A5 JP 2023537410A5 JP 2023509739 A JP2023509739 A JP 2023509739A JP 2023509739 A JP2023509739 A JP 2023509739A JP 2023537410 A5 JP2023537410 A5 JP 2023537410A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- substituted
- hydrogen
- heterocycloalkyl
- halo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063064640P | 2020-08-12 | 2020-08-12 | |
| US63/064,640 | 2020-08-12 | ||
| PCT/US2021/045474 WO2022035923A1 (en) | 2020-08-12 | 2021-08-11 | Oxopyrrolidine urea fpr2 agonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023537410A JP2023537410A (ja) | 2023-08-31 |
| JP2023537410A5 true JP2023537410A5 (enExample) | 2024-08-19 |
| JP7802765B2 JP7802765B2 (ja) | 2026-01-20 |
Family
ID=77595649
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023509739A Active JP7802765B2 (ja) | 2020-08-12 | 2021-08-11 | オキソピロリジン尿素ｆｐｒ２アゴニスト |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US12565483B2 (enExample) |
| EP (1) | EP4196471A1 (enExample) |
| JP (1) | JP7802765B2 (enExample) |
| KR (1) | KR20230051525A (enExample) |
| CN (1) | CN116057055B (enExample) |
| WO (1) | WO2022035923A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120957970A (zh) * | 2023-04-18 | 2025-11-14 | 百时美施贵宝公司 | 碳环苯基吡咯烷酮脲fpr2激动剂 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ752095A (en) | 2013-11-28 | 2022-07-01 | Kyorin Seiyaku Kk | Urea derivative or pharmacologically acceptable salt thereof |
| US10858314B2 (en) | 2015-05-27 | 2020-12-08 | Kyorin Pharmaceutical Co., Ltd. | Urea derivative or pharmacologically acceptable salt thereof |
| US10525058B2 (en) | 2015-05-27 | 2020-01-07 | Kyorin Pharmaceutical Co., Ltd | Urea derivative or pharmacologically acceptable salt thereof |
| JP2018538367A (ja) | 2015-11-24 | 2018-12-27 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ホルミルペプチド受容体２／リポキシンａ４受容体（ｆｐｒ２／ａｌｘ）の心臓疾患を治療するための標的設定 |
| KR102772801B1 (ko) * | 2015-12-10 | 2025-02-24 | 브리스톨-마이어스 스큅 컴퍼니 | 피페리디논 포르밀 펩티드 2 수용체 및 포르밀 펩티드 1 수용체 효능제 |
| JP2020015664A (ja) * | 2016-11-21 | 2020-01-30 | 宇部興産株式会社 | 含窒素多環式ヘテロ環誘導体 |
| MX2019013926A (es) | 2017-05-22 | 2020-01-20 | Bristol Myers Squibb Co | Uso novedoso de un agonista del receptor 2 de formil peptido/receptor a4 de lipoxina (fpr2/alx) para el tratamiento de insuficiencia cardiaca. |
| CN110996950B (zh) | 2017-06-09 | 2023-04-04 | 百时美施贵宝公司 | 哌啶酮甲酰基肽2受体激动剂和甲酰基肽1受体激动剂 |
| ES2869129T3 (es) | 2017-06-09 | 2021-10-25 | Bristol Myers Squibb Co | Agonistas de piperidinona del receptor 2 de péptidos formilados |
| EP3634958B1 (en) * | 2017-06-09 | 2021-07-21 | Bristol-Myers Squibb Company | Cyclopropyl urea formyl peptide 2 receptor and formyl peptide 1 receptor agonists |
| KR102615099B1 (ko) | 2017-06-09 | 2023-12-15 | 브리스톨-마이어스 스큅 컴퍼니 | 아릴 헤테로시클릭 피페리디논 포르밀 펩티드 2 수용체 및 포르밀 펩티드 1 수용체 효능제 |
| SG11202008504SA (en) * | 2018-03-05 | 2020-10-29 | Bristol Myers Squibb Co | Phenylpyrrolidinone formyl peptide 2 receptor agonists |
| ES2964299T3 (es) * | 2018-11-26 | 2024-04-05 | Bristol Myers Squibb Co | Derivados de pirrolidinona como agonistas del receptor del péptido formilado 2 |
| ES2946673T3 (es) | 2019-06-18 | 2023-07-24 | Bristol Myers Squibb Co | Agonistas del FPR2 de óxido de biaril dialquil fosfina |
| JP7700210B2 (ja) | 2020-07-09 | 2025-06-30 | ブリストル－マイヤーズ スクイブ カンパニー | ピラゾロンホルミルペプチド２受容体アゴニスト |
| KR20230038515A (ko) | 2020-07-09 | 2023-03-20 | 브리스톨-마이어스 스큅 컴퍼니 | 옥소피롤리딘 fpr2 효능제 |
| KR20230084530A (ko) | 2020-10-09 | 2023-06-13 | 브리스톨-마이어스 스큅 컴퍼니 | 아미노이미다졸 fpr2 효능제 |
-
2021
- 2021-08-11 JP JP2023509739A patent/JP7802765B2/ja active Active
- 2021-08-11 US US18/040,831 patent/US12565483B2/en active Active
- 2021-08-11 WO PCT/US2021/045474 patent/WO2022035923A1/en not_active Ceased
- 2021-08-11 CN CN202180056346.1A patent/CN116057055B/zh active Active
- 2021-08-11 EP EP21763467.4A patent/EP4196471A1/en active Pending
- 2021-08-11 KR KR1020237008160A patent/KR20230051525A/ko active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024050527A5 (enExample) | ||
| RU2007124681A (ru) | Производные тетрагидропирана в качестве противодиабетических средств | |
| US5681824A (en) | Substituted liposaccharides useful in the treatment and prevention of endotoxemia | |
| FI89356B (fi) | Foerfarande foer framstaellnig av blodsockerhalten saenkande samt atherosklerosis hindrande tiazolidindioner | |
| JPH0550516B2 (enExample) | ||
| JP2024540164A5 (enExample) | ||
| JP2019531320A5 (enExample) | ||
| US20090131677A1 (en) | Substituted beta-phenyl-alpha-hydroxy-propanoic acid, synthesis method and use thereof | |
| JP2024540163A5 (enExample) | ||
| JP2021528451A5 (enExample) | ||
| JP3179599B2 (ja) | 縮合ベンゼンオキシ酢酸誘導体およびそれらを有効成分として含有する薬剤 | |
| DE69434720T2 (de) | Verwendung von 2,6-Dialkyl-4-Silyl-Phenol Derivaten zur Behandlung von Xanthom | |
| JP2024543013A5 (enExample) | ||
| JP2023533037A5 (enExample) | ||
| JP2691679B2 (ja) | オキシム誘導体およびそれを含有する医薬品 | |
| JPS60208975A (ja) | 血小板活性化因子拮抗剤である新規２，５−ジアリ−ルテトラヒドロチオフエン類及びその類縁体 | |
| JP2021520394A5 (enExample) | ||
| JP2022537350A5 (enExample) | ||
| JPH01501551A (ja) | 新規な医薬用途 | |
| PT650485E (pt) | 2,5-diaril-tetra-hidro-tiofenos -furanos e analogos para o tratamento de desordens inflamatorias e imunitarias | |
| JP4443036B2 (ja) | ピラジン誘導体、それらの製造及びそれらを含有する薬剤 | |
| US6835846B2 (en) | Aliphatic compounds, process for their preparation and their usage | |
| JP2024540161A5 (enExample) | ||
| WO1994004546A1 (fr) | Derive de moranoline | |
| JP2024546946A5 (enExample) |